ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in
(C) 2024 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
297 GBX | +7.22% | +2.06% | +4.95% |
Jul. 09 | Transcript : HUTCHMED Limited - Special Call | |
Jul. 05 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in
(C) 2024 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+4.95% | 3.29B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |